CompletedNot Applicable

Zika and Neurodevelopment Among Infants in Grenada

Grenada148 participantsStarted 2018-09-03

Plain-language summary

Implement a randomized controlled trial, evidence-based, culturally adapted, environmental enrichment intervention for the purpose of enhancing neurocognitive outcomes among Zika Exposed Children.

Who can participate

Age range24 Months – 30 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must be actively enrolled in the pre-existing Zika Cohort Study * Infant must be alive and living with a parent/guardian at the time of recruitment * Infant must be between 24-27 months at the time of recruitment Exclusion Criteria: * Any infants older than 27 months * Persons not enrolled in the pre-existing Zika Cohort Study

What they're measuring

The INTERGROWTH 21st Neurodevelopmental Assessment (INTER-NDA)

Timeframe: 22-30 months

Trial details

NCT IDNCT04697147

SponsorWindward Islands Research and Education Foundation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02-22

View on ClinicalTrials.gov More Zika Virus Infection trials